Transcriptomics

Dataset Information

0

Expression data from FACS-sorted CD8+BTLA+ vs CD8+BTLA- Human Tumor-infiltrating Lymphocytes in Metastatic Melanoma


ABSTRACT: Adoptive T-cell Therapy (ACT) involves using tumor-infiltrating lymphocytes (TIL) isolated from metastatic melanoma and expanding them ex vivo prior to infusion into lympho-depleted patients. This is one of the most promising approaches to treat metastatic melanoma, with the rates of clinical response between 48-50% based on studies done at NCI, M.D. Anderson Cancer Center (Houston, TX), and Sheba Medical Center (Tel Aviv, Israel). In the Phase II ACT Trial at M.D. Anderson Cancer Center , our group has uncovered an association between positive clinical response and the amount of CD8+ tumor-infiltrating lymphocytes expressing B and T Lymphocyte Attenuator (BTLA), a reported inhibitory receptor on T-cells. We used microarrays to detail the differences in the global programme of gene expression between CD8+BTLA+ vs CD8+BTLA- TILs in order to understand the molecular basis of the clinical association.

ORGANISM(S): Homo sapiens

PROVIDER: GSE43260 | GEO | 2013/01/03

SECONDARY ACCESSION(S): PRJNA185170

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2013-01-03 | E-GEOD-43260 | biostudies-arrayexpress
| PRJNA185170 | ENA
2021-11-16 | GSE138720 | GEO
2020-03-28 | GSE147620 | GEO
2013-12-31 | E-GEOD-42824 | biostudies-arrayexpress
| PRJNA576899 | ENA
2015-05-05 | E-GEOD-65627 | biostudies-arrayexpress
2019-05-06 | PXD010863 | Pride
2023-07-22 | GSE223534 | GEO
2022-12-12 | GSE207471 | GEO